CTRI/2024/03/063966招募中2 期
‘An Open-Label, Single-Arm Interventional Study to Evaluate the Safety and Efficacy of Romiplostim in Danazol Resistant/ Intolerant Inherited Bone Marrow Failure Syndromes’ - RISE
试验速览
- 阶段
- 2 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with IBMFS including Fanconi anemia, dyskeratosis congenita causing cytopenias Hb less than 8 gram per decilitre, ANC less than 500 cells or Platelet count less than 30,000 per microlitre or bone marrow cellularity less than 25 percent and with danazol resistance or intolerance
排除标准
- •Known hypersensitivity or past use of Romiplostim, history of thrombosis, patients with IBMF with co-existing myelodysplasia or malignancies and organ dysfunction; presence of FANCD mutation
研究者
相似试验
进行中（未招募）
1 期
Open-label, single arm, interventional study to explore the efficacy and safety of paliperidone ER in the management of patients with acute agitation and/or aggression - IMPACTEUCTR2009-015629-35-BEJanssen-Cilag NV/SA
尚未招募
Unknown
Evaluation of a Novel Continuous Glucose Monitoring System in Children and Adults with Type 1 and Type 2 DiabetesType 2 diabetesMetabolic and Endocrine - DiabetesType 1 diabetesACTRN12624000735550i-SENS, Inc.100
尚未招募
不适用
Evaluation of safety and tolerability of HASG-072009 Capsules in healthy peopleCTRI/2022/06/043369Himalaya Wellness Company
尚未招募
不适用
Evaluation of safety and tolerability of HASI-072011 Capsules in healthy peopleCTRI/2022/06/043405Himalaya Wellness Company
尚未招募
不适用
Evaluating the safety and tolerability of HFHP-061904 powder in healthy populatioCTRI/2022/06/043545Himalaya Wellness Company